Université Paris Cité, Institut National de la Santé et de la recherche médicale (Inserm) U1132 Biologie de l'os et du cartilage (BIOSCAR), Paris, France.
Faculté or Unité de formation et de recherche (UFR) d'Odontologie, Laboratoire de Neurobiologie Oro-Faciale (EA 7543), Université Paris Cité, Paris, France.
Front Endocrinol (Lausanne). 2023 Mar 14;14:1104025. doi: 10.3389/fendo.2023.1104025. eCollection 2023.
The aim of this systematic review was to determine if there exists an efficacious drug treatment for cherubism, based on published studies.
This systematic review included observational case studies reporting pharmacological management of cherubism. We developed specific search strategies for PubMed (including Medline), ScienceDirect, Web of Science. We evaluated the methodological quality of the included studies using criteria from the Joanna Briggs Institute's critical appraisal tools.
Among the 621 studies initially identified by our search script, 14 were selected for inclusion, of which five were classified as having a low risk of bias, four as having an unclear risk, and five a high risk. Overall, 18 cherubism patients were treated. The sample size in each case study ranged from one to three subjects. This review identified three types of drugs used for cherubism management: calcitonin, immunomodulators and anti-resorptive agents. However, the high heterogeneity in case reports and the lack of standardized outcomes precluded a definitive conclusion regarding the efficacy of any treatment for cherubism.
The present systematic review could not identify an effective treatment for cherubism due to the heterogeneity and limitations of the included studies. However, in response to these shortcomings, we devised a checklist of items that we recommend authors consider in order to standardize the reporting of cherubism cases and specifically when a treatment is given toward identification of an efficacious cherubism therapy.
https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022351044, identifier CRD42022351044.
本系统评价旨在根据已发表的研究确定是否存在有效的 cherubism 药物治疗方法。
本系统评价纳入了报告 cherubism 药物治疗管理的观察性病例研究。我们为 PubMed(包括 Medline)、ScienceDirect、Web of Science 制定了特定的搜索策略。我们使用 Joanna Briggs 研究所的批判性评价工具的标准评估纳入研究的方法学质量。
根据我们的搜索脚本最初确定的 621 项研究中,有 14 项被选中纳入,其中 5 项被归类为低偏倚风险,4 项为不确定风险,5 项为高偏倚风险。总体而言,有 18 名 cherubism 患者接受了治疗。每个病例研究的样本量从一个到三个受试者不等。本综述确定了用于 cherubism 管理的三种类型的药物:降钙素、免疫调节剂和抗吸收剂。然而,病例报告中的高度异质性和缺乏标准化结局使得无法确定任何 cherubism 治疗方法的疗效。
由于纳入研究的异质性和局限性,本系统评价无法确定 cherubism 的有效治疗方法。然而,针对这些不足之处,我们设计了一个检查表,建议作者在报告 cherubism 病例时考虑这些项目,特别是在给予治疗时,以便确定有效的 cherubism 治疗方法。
https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022351044,标识符 CRD42022351044。